Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC
- Citation:
- Breast Cancer Res Treat vol 117 (3) 603-609
- Year:
- 2009
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pmc-release
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- Parents:
- None
- Children:
- None
- Program:
- CCP
- Primary Committee:
- Symptom Inter
- Sec. Committees:
- Pharmas:
- Grants:
- CA 124477, N01 CA035431, U10 CA035269, CA-37404, K05 CA124477, U10 CA037404, CA-35103, CA-25224, U10 CA035415, CA-35415, U10 CA035431, CA-35269, U10 CA025224, U10 CA035103
- Corr. Author:
- Stephanie L. Hines
- Authors:
- Stephanie L. Hines Betty Mincey Todor Dentchev Jeff A. Sloan Edith A. Perez David B. Johnson Paul L. Schaefer Steve Alberts Heshan Liu Stephen Kahanic Miroslaw A. Mazurczak Daniel A. Nikcevich Charles L. Loprinzi
- Networks:
- Study
- NCCTG-N03CC
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords:
- Breast cancer, Aromatase inhibitor, Bone loss, Zoledronic acid